Prospective, multi-center, randomized, double-blind, two-arm, parallel group, active control, comparative clinical study to evaluate efficacy and safety of R-TPR- 022 / Xolair in patients with moderate to severe persistent asthma
Latest Information Update: 10 Dec 2020
At a glance
- Drugs R-TPR-022 (Primary)
- Indications Acute asthma; Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Reliance Life Sciences
- 30 Jun 2020 Status changed from active, no longer recruiting to completed.
- 05 Nov 2019 Status changed from not yet recruiting to active, no longer recruiting.
- 02 Jan 2018 New trial record